NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express
a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv)
derived from a human monoclonal antibody specific for the human tumor-associated antigen
(TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily
member 17; TNFRSF17) fused, via an as of yet unknown linker, to the co-stimulatory
domain of CD28, with potential immunostimulating and antineoplastic activities. Upon
administration, the autologous anti-BCMA CAR transduced T-cells KITE-585 specifically
recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor
for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF),
is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found
on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays
a key role in plasma cell proliferation and survival. The CD28 co-stimulatory domain
optimizes T-cell expansion and function.;